Formulation Development and Evaluation of Sustain Release Gastroretentive Floating Tablets of Pregabalin

Sri Prakash Mishra*¹, Alok Pal Jain²

1. School of Pharmacy and Research, Sitapur, (U.P.)

2. Sarvepalli Radhakrishnan University, Bhopal (M.P)

*Corresponding Author's E mail: mishrasp72@gmail.com

Received 29 April 2020; Revised 5 May 2020; Accepted 15 May 2020; Available online 15 July 2020

Cite this article as: Mishra SP, Jain AP. Formulation Development and Evaluation of Sustain Release Gastroretentive Floating Tablets of Pregabalin. Asian Journal of Pharmaceutical Education and Research. 2020; 9(3): 56-67.

<https://dx.doi.org/10.38164/AJPER/9.3.2020.56-67>

ABSTRACT

The purpose of this research was to develop a novel gastro retentive drug delivery system based on direct compression method for sustained delivery of active agent to improve the bioavailability, reduce the number of doses and to increase patient compliance. Gastro retentive floating tablets of Pregabalin (PRE) were prepared by direct compression method using altered concentrations of HPMC K4, HPMC K15 and PVP K30 as polymers. The prepared tablets of PRE were evaluated for hardness, thickness, friability, weight variation, drug content uniformity, buoyancy lag time, total floating time, *in-vitro* dissolution study, etc. All the compositions were resulted in adequate Pharmacopoeial limits. Compatibility studies was execution during FTIR shown that there was absence of probable chemical interaction between pure drug and excipients. The varying concentration of gas generating agent and polymers was found to affect on *in-vitro* drug release and floating lag time. *In vitro* drug release of floating gastro retentive tablet of PRE shown that the formulation F9 was found to be the best formulation as it releases 98.89% in a controlled manner for an extended period of time (up to 12 hrs). The release data was fitted to various mathematical models such as Higuchi, Korsmeyer-Peppas, First order and Zero order to evaluate the kinetics and mechanism of the drug release. The optimized formulation (F9) showed no significant change in physical appearance, drug content, floating lag time, *in vitro* dissolution studies after 75%±5% RH at 4⁰±2⁰C relative humidity for 6 months. Prepared floating tablets of PRE may prove to be a potential candidate for safe and effective controlled drug delivery over an extended period of time for gastro retentive drug delivery system.

Keywords: Pregabalin, Floating tablet, Gastro retentive, Total floating time.

INTRODUCTION

Oral administration is the most versatile, convenient and commonly employed route of drug delivery for systemic action. Oral controlled release drug delivery have recently been of increasing interest in pharmaceutical field to achieve improved therapeutic advantages, such as ease of dosing administration, patient compliance and flexibility in formulation. A controlled drug delivery system with prolonged

residence time in the stomach is of particular interest for drugs that are locally active in the stomach, have narrow absorption window in gastrointestinal tract, are primarily absorbed from stomach and upper part of GIT, are unstable in the intestinal or colonic environment, disturb normal colonic bacteria and exhibit low solubility at high pH values. Gastro retentive dosage form can remain in the gastric region for several hours and hence significantly prolong the gastric residence time of drugs. Prolonged gastric retention improves bioavailability, reduces drug waste and improves solubility of drugs that are less soluble in a high pH environment. Gastro retention helps to provide better availability of new products with suitable therapeutic activity and substantial benefits for patients ^{1,2}. Pregabalin (PRE; S-(3)-amino methyl hexanoic acid) is a structural analogue of γ -aminobutyric acid, which is used to treat refractory partial seizures, diabetic neuropathy, post-therapeutic neuralgia, and social anxiety disorders. Its main site of action appears to be the $\alpha_2\text{-}\delta$ subunit of the voltage-dependent calcium channels that are widely distributed throughout the peripheral and central nervous system ³⁻⁵. PRE is a highly soluble and highly permeable drug, categorized according to the biopharmaceutics classification system (BCS) as a class 1 compound. PRE has an oral bioavailability of more than 90% with an average elimination half life of 6.3 h, and it is excreted unchanged in the urine ⁶. The absorption of PRE is limited to the upper small intestine, where L-amino transporters that govern PRE absorption exclusively exist ^{7,8}. In 2004, Pfizer introduced PRE to the market under the brand name Lyrica as a conventional, immediate release (IR)-type capsule with a recommended dosage regimen of 150-600 mg per day divided into 2 or 3 doses ^{9,10}. The objective of the present research work was to provide gastroretentive formulation that will provide once daily, sustained release dosage form of PRE.

MATERIALS AND METHODS

Materials

Pregabalin was received as a gift sample from Sun Pharmaceutical Industries Limited, Mumbai, India. Hydroxypropyl methylcellulose (HPMC K4M, HPMC K15M) was procured from Meditab Specialities Pvt. Ltd., Satara. PVP K30 was purchased from S.D fine chemicals, Mumbai. Sodium bicarbonate, citric acid, magnesium stearate, talc were purchased from Mapromax, Life sciences Pvt. Ltd., Dehradun. Other solvents and chemicals used in the research were of LR grade. All the studies were carried in distilled water.

Methods

Preformulation studies

Determination of λ_{max} of Pregabalin

Accurately weighed 10 mg of drug was dissolved in 10 ml of 0.1N HCl solutions in 10 ml of volumetric flask. The resulted solution 1000 μ g/ml and from this solution 1 ml pipette out and transfer into 10 ml

volumetric flask and volume make up with 0.1N HCl solution. Prepare suitable dilution to make it to a concentration range of 10-50µg/ml Pregabalin from that take 2 ml of sample react with methyl orange and separate with chloroform. The spectrum of this solution was run in 400-800 nm range in U.V. spectrophotometer (Labindia-3000+).

Fourier Transform Infrared (FTIR) spectroscopy

The physical properties of the physical assortment were comparing with those of *Pregabalin* pure drug. Samples was assorted comprehensively through 100mg potassium bromide IR powder as well as compacted under vacuum at a pressure of concerning 12 psi for 3 minutes. The ensuing disc was mounted in an appropriate holder in Brukers Alpha IR spectrophotometer and the IR spectrum was recorded from 3500 cm to 500 cm. The resultant spectrum was compared for any spectrum changes.

Pre compression evaluation

Flow properties and compressibility properties of powder mixture were evaluated by measurement of angle of repose, bulk density, tapped density, carr's index and hausner's ratio.

Angle of repose (θ)

The angle of repose was determined by using fixed funnel method. The physical mixtures of drug with different excipients were prepared and the accurately weighed drug powder or its physical mixture was taken in a funnel. The height of the funnel was adjusted in such a way that the tip of the funnel just touches the apex of the heap of the drug powder. The powder was allowed to flow through the funnel freely onto surface. The angle of repose was calculated using the following equation.

$$\theta = \tan^{-1}(h/r)$$

Where, h and r are the height and radius of the powder cone respectively.

Bulk density

Both loose bulk density (LBD) and tapped density (TBD) were determined were calculated using the following formulas.

$$\text{LBD} = \text{Powder weight/volume of the packing}$$

$$\text{TBD} = \text{Powder weight /tapped volume of the packing}$$

Compressibility index

The compressibility index of the granules was determined by Carr's compressibility index.

$$\text{Carr's index (\%)} = [(TBD - LBD)/TBD] \times 100.$$

Hausner's ratio

Hausner's ratio is an indirect index of ease of measuring the powder flow. It was calculated by the following formula¹¹⁻¹³.

$$\text{Hausner's ratio} = \text{Tapped density/Bulk density.}$$

Formulation development of Tablets

Direct compression method

Different tablets formulations (F1-F9) were prepared by direct compression technique. All powders were passed through 40 meshes. Required quantities of drug and polymers were mixed thoroughly Magnesium stearate was added as lubricant. Talc was used as glidant. Lactose was used as diluents. Finally, the powder mix was subjected to compression after mixing uniformly in a polybag. Prior to compression, the blends were evaluated for several tests ¹⁴. The composition of PRE floating tablets was shown in Table 1.

Table 1 Formulation composition of PRE gastro retentive tablets

Excipients(mg)	F1	F2	F3	F4	F5	F6	F7	F8	F9
Pregabalin	150	150	150	150	150	150	150	150	150
HPMC K 15	80	100	120	-	-	-	40	50	60
HPMC K 4	-	-	-	80	100	120	40	50	60
PVP K30	15	15	15	15	15	15	15	15	15
Citric acid	5	5	5	5	5	5	5	5	5
NaHCO₃	20	20	20	20	20	20	20	20	20
Mg(C₁₈H₃₅O₂)₂	5	5	5	5	5	5	5	5	5
Talc	5	5	5	5	5	5	5	5	5
Lactose	70	50	30	70	50	30	70	50	30
Total Weight	350	350	350	350	350	350	350	350	350

Evaluation of tablets

All the tablets were evaluated for following different parameters which includes;

General Appearance

Five tablets from different batches were randomly selected and organoleptic properties such as color, odor, taste, shape were evaluated. Appearance was judged visually.

Thickness and diameter

Thickness and diameter of tablets were determined using Vernier caliper. Five tablets from each batch were used, and an average value was calculated.

Hardness

For each formulation, the hardness of five tablets was determined using the Monsanto hardness tester (Cadmach).

Friability

The friability of a sample of 10 tablets was measured using a Friability tester (Electro Lab). Ten tablets were weighed, rotated at 25 rpm for 4 minutes. Tablets were reweighed after removal of fines (dedusted) and the percentage of weight loss was calculated.

Uniformity of weight

Twenty tablets were randomly selected from each batch individually weighed, the average weight and standard deviation of 20 tablets was calculated.

Drug content

Twenty tablets were taken and amount of drug present in each tablet was determined. The tablets were crushed in a mortar and the powder equivalent to 100mg of drug was transferred to 100ml standard flask. The powder was dissolved in 50 ml of 0.1 N HCl and made up to volume with of 0.1 N HCl. The sample was mixed thoroughly and filtered through a 0.45 μ membrane filter. The filtered solution was diluted suitably and analyzed for drug content by UV spectrophotometer at a λ_{max} of 408 nm using of 0.1 N HCl as blank.

In vitro buoyancy studies:

In vitro buoyancy was determined by floating lag time as per the method described by Rosa *et al*¹⁵. The tablets were separately in a 100 ml glass beaker containing simulated gastric fluid (SGF), pH 1.2 as per USP. The time necessary for the tablet to increase to the outside and float was determined as floating lag time. The experiments were conducted in triplicate. Total floating times were measured during *in vitro* dissolution studies.

Dissolution rate studies

In vitro drug release of the sample was done using USP-type II dissolution apparatus (Paddle type). The dissolution medium, 900 ml 0.1N HCl was set into the dissolution flask maintaining the temperature of 37 $\pm$ 0.5 $^{\circ}$ C and rpm of 75. One PRE tablet was set in every container of dissolution apparatus. The mechanical assembly was permitted to keep running for 10 hours. Sample measuring 5 ml were pulled back after each 1 hour up to 10 hours using 10ml pipette. The new disintegration medium (37 $^{\circ}$ C) was supplanted each time with a similar amount of the sample and takes the absorbance at 408 nm using spectroscopy¹⁶⁻¹⁸.

Mathematical treatment of *in-vitro* release data: The quantitative analysis of the qualities got in dissolution/release tests is simpler when mathematical formulas that express the dissolution comes about as an element of a portion of the measurement frames attributes are utilized.

Zero-order kinetics: The pharmaceutical dosage frames following this profile release a similar measure of medication by unit of time and it is the ideal method of medication release keeping in mind the end

goal to accomplish a pharmacological prolonged action. The following relation can, in a simple way, express this model:

$$Q_t = Q_0 + K_0 t$$

where Q_t is the amount of drug dissolved in time t , Q_0 is the initial amount of drug in the solution (most times, $Q_0=0$) and K_0 is the zero order release constant.

First-order kinetics: The following relation expresses this model:

$$\log Q_t = \log Q_0 + \frac{K_1 t}{2.303}$$

where Q_t is the amount of drug dissolved in time t , Q_0 is the initial amount of drug in the solution and K_1 is the zero order release constant.

Along these lines a graphic of the decimal logarithm of the released measure of drug versus time will be linear. The pharmaceutical dosage shapes following this dissolution profile, for example, those containing water-solvent drugs in permeable frameworks, discharge drug in a way that is corresponding to the measure of drug staying in its inside, in such way, that the measure of drug released by unit of time reduce.

Higuchi model: Higuchi built up a few theoretical models to ponder the arrival of water-solvent and low dissolvable medications in semi-strong or potentially strong grids. Mathematical expressions were acquired for sedate particles scattered in a uniform grid acting as the diffusion media. The simplified Higuchi model is expressed as:

$$Q = K_H \cdot t^{1/2}$$

Where Q is the amount of drug released in time t and K_H is the Higuchi dissolution constant. Higuchi model describes drug release as a diffusion process based in the Fick's law, square root time dependent. This relation can be utilized to portray the drug dissolution from a few kinds of modified release pharmaceutical dosage structures, for example, transdermal systems and matrix tablets with water-dissolvable drugs.

Korsmeyer-Peppas model: Korsmeyer *et al.* used a simple empirical equation to describe general solute release behaviour from controlled release polymer matrices:

$$\frac{M_t}{M_\infty} = a t^n$$

where M_t/M_∞ is fraction of drug released, a is kinetic constant, t is release time and n is the diffusional exponent for drug release. 'n' is the slope value of $\log M_t/M_\infty$ versus $\log$ time curve. Peppas stated that the above equation could adequately describe the release of solutes from slabs, spheres, cylinders and

discs, regardless of the release mechanism. Peppas used this n value in order to characterize different release mechanisms, concluding for values for a slab, of $n = 0.5$ for fickian diffusion and higher values of n , between 0.5 and 1.0, or $n = 1.0$, for mass transfer following a non-fickian model. In case of a cylinder $n = 0.45$ instead of 0.5, and 0.89 instead of 1.0. This equation can only be used in systems with a drug diffusion coefficient fairly concentration independent. To the determination of the exponent n the portion of the release curve where $M_t/M_\infty < 0.6$ should only be used. To use this equation, it is also necessary that release occurs in a one-dimensional way and that the system width-thickness or length-thickness relation be at least 10. A modified form of this equation was developed to accommodate the lag time (l) in the beginning of the drug release from the pharmaceutical dosage form:

$$\frac{M_{t,l}}{M_\infty} = a (t - l)^n$$

When there is the possibility of a burst effect, b , this equation becomes:

$$\frac{M_t}{M_\infty} = at^n + b$$

In the absence of lag time or burst effect, l and b value would be zero and only at^n is used. This mathematical model, also known as *Power Law*, has been used very frequently to describe release from several different pharmaceutical modified release dosage forms¹⁹⁻²¹.

Stability studies

The optimized formulation of PRE were packed in strips of 0.04 mm thick aluminium foil laminated with poly vinyl chloride by strip packing and these packed formulations were stored in ICH certified stability chambers (Thermo labs, Mumbai) maintained at 4⁰ C and 75% RH for 6 months. The samples were withdrawn periodically and evaluated for their floating lag time, content uniformity and for *in vitro* drug release.

Results and discussion

The $\lambda_{\max}$ of PRE was found to be 408 nm by using U.V. spectrophotometer (Labindia-3000+) in linearity range 10-50µg/ml Figure 1. Identification of PRE was done by FTIR spectroscopy with respect to marker compound. It was identified from the result of IR spectrum as per specification. Tablet powder blend was subjected to various pre-formulation parameters Table 2. The angle of repose values indicates that the powder blend has good flow properties. The bulk density and tapped density of all the formulations was found to be in the range of 0.349 to 0.365 (gm/ml) and 0.438 to 0.485 showing that the powder has good flow properties. The compressibility index of all the formulations was found to be ranging between 20.320 to 26.186 which show that the powder has good flow properties. All the formulations have shown the Hauser's ratio ranging between 1.255 to 1.355 indicating the powder has good flow properties. PRE

tablet quality control tests such as weight variation, hardness and friability, thickness, drug content and drug release studies in different media were performed on the compression tablet. All the parameters such as weight variation, hardness, friability, thickness and drug content were found to be within limits Table 3.

Figure 1 Determination of $\lambda_{\max}$ of Pregabalin in 0.1N HCl

Table 2 Result of pre-compression properties of PRE FGR tablets

Formulation code	Bulk density(gm/ml)	Tapped density(gm/ml)	Compressibility index	Hausner's ratio
F1	0.356	0.462	22.944	1.298
F2	0.359	0.458	21.616	1.276
F3	0.365	0.469	22.175	1.285
F4	0.362	0.472	23.305	1.304
F5	0.358	0.485	26.186	1.355
F6	0.359	0.478	24.895	1.331
F7	0.354	0.469	24.520	1.325
F8	0.358	0.458	21.834	1.279
F9	0.349	0.438	20.320	1.255

Table 3 Results of post compression properties of PRE FGR tablets

F. Code	Thickness (mm)	Diameter (mm)	Hardness (kg/cm ²) N=3	Weight variation (mg)	Friability (%)	Drug content (%)
F1	3.46±0.12	9.8±0.1	4.8±0.1	355±4	0.589±0.002	98.85±0.25
F2	3.50±0.09	9.6±0.2	4.6±0.2	350±6	0.685±0.005	96.65±0.14
F3	3.47±0.11	9.8±0.1	4.7±0.1	345±3	0.458±0.004	99.56±0.23
F4	3.48±0.23	9.7±0.2	4.8±0.3	350±4	0.658±0.006	98.25±0.14
F5	3.49±0.14	9.8±0.1	4.6±0.2	352±5	0.521±0.007	97.85±0.26
F6	3.45±0.08	9.6±0.1	4.5±0.4	348±3	0.658±0.008	98.98±0.41
F7	3.44±0.07	9.5±0.1	4.8±0.2	359±5	0.965±0.007	99.12±0.52
F8	3.43±0.05	9.7±0.2	4.7±0.1	348±4	0.658±0.004	99.45±0.32
F9	3.46±0.09	9.8±0.1	4.8±0.1	354±3	0.785±0.005	99.36±0.28

*Average of three determinations (Mean±S.D)

In the present study 9 formulations with variable concentration of polymers (HPMC K4, K 15) were prepared by direct compression method and evaluated for physicochemical properties. The results of buoyancy lag time, total floating time and *in vitro* drug release was given in Table 4, 5 & Figure 3. The results indicated that optimizes formulation F9 on immersion in 0.1N HCl at $37\pm0.5^{\circ}\text{C}$ tablets immediately and remain buoyant up to 12hr without disintegration. These 2 factors are essential for tablets to acquire density < 1, so that it remains buoyant on the gastric fluids. The *in vitro* drug release data of the optimized formulation was subjected to goodness of fit test by linear regression analysis according to zero order, first order kinetic equation, Higuchi's and Korsmeyer's models in order to determine the mechanism of drug release. When the regression coefficient values of were compared, it was observed that ' r^2 ' values of Korsmeyer Peppas was maximum i.e. 0.977 hence indicating drug release from formulations was found to follow Korsmeyer Peppas model. Table 6, 7.

Table 4 Results of *in-vitro* buoyancy study of PRE FGR Floating time

Formulation Code	Floating lag times (sec)	Total floating duration (h)
F1	65	12 Hrs.
F2	69	12 Hrs.
F3	85	12 Hrs.
F4	69	12 Hrs.
F5	45	12 Hrs.
F6	52	12 Hrs.
F7	39	12 Hrs.
F8	49	12 Hrs.
F9	55	12 Hrs.

Table 5 *In-vitro* drug release study of GRF tablets

Time (hr)	% Cumulative Drug Release								
	F1	F2	F3	F4	F5	F6	F7	F8	F9
0.5	48.56	45.58	40.25	38.89	36.25	33.25	28.45	26.65	23.36
1	78.89	75.56	68.98	49.98	42.25	40.56	36.45	30.35	26.69
1.5	89.98	82.23	79.78	65.58	58.98	50.56	45.58	40.56	38.78
2	96.56	95.56	88.78	78.89	75.58	70.25	65.56	61.25	45.25
3		98.98	95.56	90.12	88.98	81.25	73.32	70.25	55.56
4			98.89	95.56	95.56	90.25	88.98	83.25	68.89
6				98.89	99.89	98.65	98.45	93.56	78.58
8								98.78	89.98
12									98.89

Figure 3 *In-vitro* drug release study of GRF tabletsTable 6 *In-vitro* drug release data for optimized formulation F9

Time (h)	Square Root of Time(h) ^{1/2}	Log Time	Cumulative*% Drug Release	Log Cumulative % Drug Release	Cumulative % Drug Remaining	Log Cumulative % Drug Remaining
0.5	0.707	-0.301	23.36	1.368	76.64	1.884
1	1	0	26.69	1.426	73.31	1.865
1.5	1.225	0.176	38.78	1.589	61.22	1.787
2	1.414	0.301	45.25	1.656	54.75	1.738
3	1.732	0.477	55.56	1.745	44.44	1.648
4	2	0.602	68.89	1.838	31.11	1.493
6	2.449	0.778	78.58	1.895	21.42	1.331
8	2.828	0.903	89.98	1.954	10.02	1.001
12	3.464	1.079	98.89	1.995	1.11	0.045

Table 7 Regression analysis data of pregabalin floating tablets

Batch	Zero Order	First Order	Higuchi	Korsmeyer Peppas
	R ²	R ²	R ²	R ²
F9	0.895	0.959	0.975	0.977

Conclusion

PRE floating tablets were successfully formulated by floating technique. The optimized formulation (F9) was selected on the basis of *in vitro* buoyancy and *in vitro* drug release. The addition of gel forming agent and gas generating agent was essential to achieve *in vitro* buoyancy. The results of the *in vitro* drug

release and *in vitro* buoyancy study showed that the optimized formulation (F9) sustained the drug release (98.89%) up to 12 hrs and remained buoyant for >12 hrs. Optimized formulation (F9) does not show any significant change in physical appearance, floating properties and drug release after storage at 40°C/75% RH and stable for 3 months.

References

1. Nayak AK, Maji R, Das B. Gastroretentive drug delivery systems: a review. *Asian J Pharm Clin Res.* 2010; 3:2-10.
2. Khan FN, Dehghan MHG. Gastroretentive drug delivery systems: a patent perspective. *Int J Health Res.* 2009; 2:23-44.
3. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. *J. Biol. Chem.* 1996; 271: 5768-5776.
4. Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. *Med. Res. Rev.* 1999; 19: 149-177.
5. Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, Walker LC. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. *Brain Res.* 2006; 1075: 68-80.
6. French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose– response trial of pregabalin adjunctive therapy in patients with partial seizures. *Neurology.* 2003; 60: 1631-1637.
7. Su TZ, Feng MR, Weber ML. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco- 2 cells. *J. Pharmacol. Exp. Ther.* 2005; 313: 1406-1415.
8. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA. XP13512 [(+/-)-1- ((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. *J. Pharmacol. Exp. Ther.* 2004; 311, 315-323.
9. NDA 21446. Lyrica (Pregabalin) Capsules Clinical Pharmacology Biopharmaceutics Review(s). CDER, U.S. Food and Drug Administration, December 30, 2004.
10. Dworkin RH, Kirkpatrick P. Pregabalin. *Nat. Rev. Drug Discov.* 2005; 4: 455-456.

11. Sinko PJ. Physical Pharmacy and Pharmaceutical Sciences, Lippincott Williams and Wilkins, 5th Edition, 2006.
12. Chein YW. Novel drug delivery systems, *Marcel Dekker, INC*, 2nd edition. 1992; 140.
13. Liberman HA, Lachman L, Schwartz JB. Pharmaceutical dosage forms: Tablets, 3rd edition, Marcel Dekker, New York. 1990.
14. Ambati BR, Samyuktha Rani B, Eswar Tony D and Sivanaga Raja D. Aceclofenac Floating Tablets- A Promising Sustained Release Dosage Form. *International Journal of Drug Development and Research*. 20113; 290-300.
15. Rosa M, Zia H, Rhodes T. Dosing and testing *in-vitro* of a bioadhesive and floating drug delivery system for oral application. *Int J Pharm*. 1994; 105:65–70.
16. Rajesh K, Usharani E and Nagaraju R. Design and evaluation of sustained release floating tablets for the treatment of gastric ulcer. *Journal of Pharmaceutical Sciences and Research*. 2009; 1(4): 81-87.
17. Patil JM, Hirlekar RS and Gide P S. Trends in floating drug delivery systems. *Journal of Scientific and Industrial Research*. 2006; 65(01): 11-21.
18. Ritger PL, Peppas NA. A Simple Equation for Description of Solute release fickian and anomalous release from swellable devices. *Journal of Controlled Release*. 1987; 5(1): 37-42.
19. Brahamankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics e a treatise, pharmacokinetics: basic consideration. 2nd ed. Vallabh Prakashan. 2009; 240e3.
20. Higuchi T. Mechanism of sustained action medication, theoretical analysis of rate of release of solid drugs dispersed in solid matrices. *J Pharm Sci*. 1963; 52:1145-9.
21. Korsmeyer RW, Gummy R, Doelker E, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymer. *Int J Pharm*. 1983; 15:25-35.